Biotech Pipelines: Prices Never Lower
Pharmaceutical companies love to deals early, at R&D stage, or late, when products are ready to be marketed. But they hate doing deals in the middle. Why? The risk to too high. Everyone knows what to expect from late stage deals; and no one's going to get killed for an early-stage deal that goes wrong. But Phase I and II deals often carry high price tags and chancy pay-offs.
You may also be interested in...
Manufacturers in the past haven't paid much heed to health plans' half-hearted efforts to reign in biotech drug spending. They figure if the drug is good enough, payers have to cover it. But health plans are for the first time serious about managing specialty pharma spending. Manufacturers should take heed because the impact on their revenues and marketing strategies could be significant.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.